Aesther Healthcare Acquisition Corp. Announces Intention To Extend Period To Consummate Business Combination
Aesther Healthcare Acquisition Corp. Announces Intention To Extend Period To Consummate Business Combination
New York, NY and Providence, RI, Dec. 13, 2022 (GLOBE NEWSWIRE) -- As previously announced, on August 31, 2022, Aesther Healthcare Acquisition Corp. ("Aesther") (NASDAQ:AEHA) entered into definitive merger agreement with Ocean Biomedical, Inc. Aesther announced today that its Board of Directors has approved an extension of the period of time available to Aesther to consummate a business combination by three months from December 16, 2022 to March 16, 2022 (the "Second Extension"), as permitted under Aesther's governing documents. In connection with the Second Extension, Aesther's sponsor, Aesther Healthcare Sponsor, LLC, has agreed to deposit an aggregate of $1,050,000 into Aesther's Trust account for its public stockholders, representing $0.10 per public share, by December 16, 2022, which will be in the form of a loan. Aesther's governing documents permit a total of two three-month extensions, of which this is the second.
纽约州纽约和罗得岛州普罗维登斯，2022年12月13日（GLOBE NEWSWIRE）——正如先前宣布的那样，Aesther Healthcare 收购公司（“Aesther”）（纳斯达克股票代码：AEHA）于2022年8月31日与海洋生物医学公司签订了最终合并协议。Aesther今天宣布，其董事会已批准将Aesther完成业务合并的时间从12月16日起延长三个月，2022年至2022年3月16日（“第二次延期”），这是Aesther管理文件所允许的。关于第二次延期，Aesther的赞助商Aesther Healthcare Sponsor, LLC已同意在2022年12月16日之前以贷款的形式向Aesther的信托账户存入总额为105万美元，相当于每股公共股东0.10美元。Aesther的管理文件允许总共延期两次，为期三个月，这是第二次延期。
